Logo Image
Publication|Articles|December 8, 2025

Supplements and Featured Publications

  • Integrating MDM2 Inhibition Into Myelofibrosis Management
  • Volume 1
  • Issue 1

Predicting Suboptimal Ruxolitinib Response in Myelofibrosis: Lessons To Be Learned from the POIESIS Trial

Predicting Suboptimal Ruxolitinib Response in Myelofibrosis: Lessons To Be Learned from the POIESIS Trial

Articles in this issue

11 months ago

The Future of Myelofibrosis: Emerging Therapies and Combination Strategies to Watch

11 months ago

Identifying Early Loss of JAK Inhibitor Response in Myelofibrosis: Current and Emerging Predictors

over 1 year ago

Navtemadlin Will Be Evaluated as Add-On Therapy to Ruxolitinib in Myelofibrosis

over 1 year ago

Dr Vachhani on the Rationale for Evaluating Navtemadlin as a Ruxolitinib Add-On in Myelofibrosis

almost 2 years ago

Navtemadlin-Based Therapy Could Drive Change in the Myelofibrosis Treatment Paradigm

almost 2 years ago

Dr Mascarenhas on Prior Data Showing the Efficacy of Navtemadlin in R/R Myelofibrosis